{"id":{"repo_id":"mississippi","oai_identifier":"oai:egrove.olemiss.edu:etd-2592"},"canonical_url":"https://search.dev.ndltd.org/etd/mississippi/oai:egrove.olemiss.edu:etd-2592","repository":{"repo_id":"mississippi","name":"University of Mississippi","base_url":"https://egrove.olemiss.edu/do/oai/"},"display":{"title":"Design of Thermosensitive Hydrogel for Extended-Release of Praziquantel","abstract":"Parasitic diseases are a severe threat to people and animals. Praziquantel is the most comanti-parasitic drug with high efficiency, and it has been used to treat parasitic diseases for many years. However, it has very strong gastrointestinal and liver metabolism that leads to a strong first-pass effect and a short half-life. Additionally, the frequent oral administration was inconvenient for the large livestock. To overcome these drawbacks, this study aimed to develop an extended-release thermosensitive hydrogel formulation that was applicable to the injectable administration. The praziquantel-loaded hydrogel formulation based on poloxamer 407 (20%, w/v) was prepared, and two strategies for modifications of poloxamer 407 hydrogel were studied. One of them was the formulation consisting of PEG-DSPE/TPGS mixed micelles-poloxamer 407 hydrogel hybrid system; another was the poloxamer 407 hydrogel adding with HPMC as an adhesive. These hydrogel formulations had a reversible sol-gel transition property at approximate 26 °C and obtained high loading efficiencies and storage stability. <em>in-vitro</em> release studies, as well as <em>in-vivo</em> pharmacokinetic studies, were conducted to evaluate the extended-release effect, and the bioavailability of several optimized formulations of praziquantel was calculated. The <em>in-vitro</em> release of praziquantel was prolonged when loading into poloxamer 407 hydrogel. Both the modifications of poloxamer 407 hydrogel, by adding HPMC as well as utilizing PEG- DSPE/TPGS mixed micelle as a secondary delivery vehicle obtained the relatively better extended-release profiles than the original poloxamer 407 hydrogel. The pharmacokinetic studies indicated that the poloxamer 407 hydrogel formulation has a relatively high bioavailability and prolonged release profile, but both two modifications failed to obtain a significant improvement of an extended-release characteristic compared with the original hydrogel solution.","abstract_html":"Parasitic diseases are a severe threat to people and animals. Praziquantel is the most comanti-parasitic drug with high efficiency, and it has been used to treat parasitic diseases for many years. However, it has very strong gastrointestinal and liver metabolism that leads to a strong first-pass effect and a short half-life. Additionally, the frequent oral administration was inconvenient for the large livestock. To overcome these drawbacks, this study aimed to develop an extended-release thermosensitive hydrogel formulation that was applicable to the injectable administration. The praziquantel-loaded hydrogel formulation based on poloxamer 407 (20%, w/v) was prepared, and two strategies for modifications of poloxamer 407 hydrogel were studied. One of them was the formulation consisting of PEG-DSPE/TPGS mixed micelles-poloxamer 407 hydrogel hybrid system; another was the poloxamer 407 hydrogel adding with HPMC as an adhesive. These hydrogel formulations had a reversible sol-gel transition property at approximate 26 °C and obtained high loading efficiencies and storage stability. &lt;em&gt;in-vitro&lt;/em&gt; release studies, as well as &lt;em&gt;in-vivo&lt;/em&gt; pharmacokinetic studies, were conducted to evaluate the extended-release effect, and the bioavailability of several optimized formulations of praziquantel was calculated. The &lt;em&gt;in-vitro&lt;/em&gt; release of praziquantel was prolonged when loading into poloxamer 407 hydrogel. Both the modifications of poloxamer 407 hydrogel, by adding HPMC as well as utilizing PEG- DSPE/TPGS mixed micelle as a secondary delivery vehicle obtained the relatively better extended-release profiles than the original poloxamer 407 hydrogel. The pharmacokinetic studies indicated that the poloxamer 407 hydrogel formulation has a relatively high bioavailability and prolonged release profile, but both two modifications failed to obtain a significant improvement of an extended-release characteristic compared with the original hydrogel solution.","abstract_has_math":false,"creators":["Feng, Sheng"],"institution":null,"degree_name":"M.S. in Pharmaceutical Science","degree_level":"Thesis","degree_discipline":"Pharmaceutics and Drug Delivery","degree_department":null,"school":null,"contributors":["Chalet Tan","Walter Chambliss","Seongbong Jo"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-01-01T08:00:00Z","date_published":"2019-01-01T08:00:00Z","updated_at":"2026-07-24T03:07:00Z","subjects":["extended-release","hydrogel","poloxamer","praziquantel","Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://egrove.olemiss.edu/etd/1593","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Chalet Tan","Walter Chambliss","Seongbong Jo"]},{"key":"dc:creator","label":"Author","values":["Feng, Sheng"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2020-01-23T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutics and Drug Delivery"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S. in Pharmaceutical Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["extended-release","hydrogel","poloxamer","praziquantel","Pharmacy and Pharmaceutical Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://egrove.olemiss.edu/etd/1593"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Parasitic diseases are a severe threat to people and animals. Praziquantel is the most comanti-parasitic drug with high efficiency, and it has been used to treat parasitic diseases for many years. However, it has very strong gastrointestinal and liver metabolism that leads to a strong first-pass effect and a short half-life. Additionally, the frequent oral administration was inconvenient for the large livestock. To overcome these drawbacks, this study aimed to develop an extended-release thermosensitive hydrogel formulation that was applicable to the injectable administration. The praziquantel-loaded hydrogel formulation based on poloxamer 407 (20%, w/v) was prepared, and two strategies for modifications of poloxamer 407 hydrogel were studied. One of them was the formulation consisting of PEG-DSPE/TPGS mixed micelles-poloxamer 407 hydrogel hybrid system; another was the poloxamer 407 hydrogel adding with HPMC as an adhesive. These hydrogel formulations had a reversible sol-gel transition property at approximate 26 °C and obtained high loading efficiencies and storage stability. <em>in-vitro</em> release studies, as well as <em>in-vivo</em> pharmacokinetic studies, were conducted to evaluate the extended-release effect, and the bioavailability of several optimized formulations of praziquantel was calculated. The <em>in-vitro</em> release of praziquantel was prolonged when loading into poloxamer 407 hydrogel. Both the modifications of poloxamer 407 hydrogel, by adding HPMC as well as utilizing PEG- DSPE/TPGS mixed micelle as a secondary delivery vehicle obtained the relatively better extended-release profiles than the original poloxamer 407 hydrogel. The pharmacokinetic studies indicated that the poloxamer 407 hydrogel formulation has a relatively high bioavailability and prolonged release profile, but both two modifications failed to obtain a significant improvement of an extended-release characteristic compared with the original hydrogel solution."]},{"key":"dc:title","label":"Title","values":["Design of Thermosensitive Hydrogel for Extended-Release of Praziquantel"]}]}],"canonical_facts":{"dc:contributor":["Chalet Tan","Walter Chambliss","Seongbong Jo"],"dc:creator":["Feng, Sheng"],"dc:date.available":["2020-01-23T08:00:00Z"],"dc:description.abstract":["Parasitic diseases are a severe threat to people and animals. Praziquantel is the most comanti-parasitic drug with high efficiency, and it has been used to treat parasitic diseases for many years. However, it has very strong gastrointestinal and liver metabolism that leads to a strong first-pass effect and a short half-life. Additionally, the frequent oral administration was inconvenient for the large livestock. To overcome these drawbacks, this study aimed to develop an extended-release thermosensitive hydrogel formulation that was applicable to the injectable administration. The praziquantel-loaded hydrogel formulation based on poloxamer 407 (20%, w/v) was prepared, and two strategies for modifications of poloxamer 407 hydrogel were studied. One of them was the formulation consisting of PEG-DSPE/TPGS mixed micelles-poloxamer 407 hydrogel hybrid system; another was the poloxamer 407 hydrogel adding with HPMC as an adhesive. These hydrogel formulations had a reversible sol-gel transition property at approximate 26 °C and obtained high loading efficiencies and storage stability. <em>in-vitro</em> release studies, as well as <em>in-vivo</em> pharmacokinetic studies, were conducted to evaluate the extended-release effect, and the bioavailability of several optimized formulations of praziquantel was calculated. The <em>in-vitro</em> release of praziquantel was prolonged when loading into poloxamer 407 hydrogel. Both the modifications of poloxamer 407 hydrogel, by adding HPMC as well as utilizing PEG- DSPE/TPGS mixed micelle as a secondary delivery vehicle obtained the relatively better extended-release profiles than the original poloxamer 407 hydrogel. The pharmacokinetic studies indicated that the poloxamer 407 hydrogel formulation has a relatively high bioavailability and prolonged release profile, but both two modifications failed to obtain a significant improvement of an extended-release characteristic compared with the original hydrogel solution."],"dc:identifier":["https://egrove.olemiss.edu/etd/1593"],"dc:subject":["extended-release","hydrogel","poloxamer","praziquantel","Pharmacy and Pharmaceutical Sciences"],"dc:title":["Design of Thermosensitive Hydrogel for Extended-Release of Praziquantel"],"thesis:degree_discipline":["Pharmaceutics and Drug Delivery"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["M.S. in Pharmaceutical Science"]},"updated_at":"2026-07-24T03:07:00Z"}